Piramal Pharma Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company also confirmed key leadership reappointments, including the Chairperson and Executive Director, alongside strategic governance updates. Despite challenges, the company continues its growth trajectory, focusing on its global pharmaceutical portfolio and operational strategy.
Financial Performance Highlights
For the fiscal year ended March 31, 2026, Piramal Pharma reported a standalone total income of ₹5,444.74 crore, compared to ₹5,493.06 crore in the previous year. The standalone net profit stood at ₹700.01 crore, reflecting a steady performance from ₹691.40 crore in the previous year. Consolidated figures indicate a total income of ₹9,082.38 crore for the year ended March 31, 2026, with a consolidated net loss of ₹325.94 crore, largely impacted by exceptional items, including an impairment charge of ₹175.82 crore recognized during the annual assessment.
Leadership and Governance Updates
The Board of Directors has approved several key leadership reappointments to ensure strategic continuity:
- Ms. Nandini Piramal has been reappointed as Whole-Time Director, designated as Executive Director and Chairperson, for a period of 3 years effective April 1, 2027.
- Mr. Peter DeYoung has been reappointed as Whole-Time Director, designated as Executive Director, for 3 years effective October 6, 2026.
- Mr. Sridhar Gorthi and Mr. Peter Stevenson have been reappointed as Non-Executive, Independent Directors for a second term of 5 years, effective March 30, 2027.
Operational Changes
In a move to strengthen corporate secretarial functions, the company has appointed Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026. Additionally, the company is shifting its registered office address in Mumbai to the Ananta Building, Piramal Corporate Park, with the change becoming effective on April 30, 2026. These changes reflect the company’s commitment to optimizing its corporate infrastructure.
Source: BSE
